Navigation Links
Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Date:1/28/2008

Published Paper Provides Rationale for Continued Development of CNDO103 as

Cancer Treatment

SAN DIEGO, Jan. 28 /PRNewswire/ -- Coronado Biosciences Inc. today announced the publication of data demonstrating that the Bcl-2 inhibitor, Apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than Gossypol in vivo in mice.

Published online in Blood (Jan. 17, DOI 10.1182/blood-2007-09-113647) by the Burnham Institute's president and CEO, John Reed, M.D., Ph.D., and collaborators, the paper summarized study findings demonstrating that mice treated with Apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with Gossypol. The results support Coronado Biosciences' continued development of its lead candidate, CNDO103, as a cancer treatment.

"Apogossypol was rationally designed to eliminate the toxicities seen with Gossypol," said Reed. "This study provides strong evidence that Apogossypol is better tolerated by the animals without a compromise in potency in vitro. We hope these preclinical results translate to humans. If they do, Apogossypol can play a role in the treatment of many types of cancers."

Maurizio Pellecchia, Ph.D., a professor at the Burnham Institute of Medical Research, developed Apogossypol using NMR guided rational drug design. "Based on our molecular modeling, we predicted that Apogossypol would be equally potent in killing cancer cells but safer than the parent compound Gossypol," said Pellecchia. "It is gratifying that the exhaustive set of experiments reported in the paper support our predictions."

RJ Tesi, M.D., president and CEO of Coronado Biosciences, added: "The data reinforce our decision to push rapidly to the clinic with Apogossypol. We plan to perform IND-enabling preclinical studies for Apogossypol, CNDO103, in the first half of the year. If the toxicity profile in animals approximates what was
'/>"/>

SOURCE Coronado Biosciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... AMES, Iowa - Researchers at the U.S. Department ... a potentially perfect way to sort and distribute ... over optical fibers to people ,throughout the world. ... filter, promises greatly enhanced transmission of multiple ,wavelength ...
... Feb. 18 - Biotech pioneer,William J. Rutter, PhD, ... RAPS,Horizons Conference & Exhibition in San Francisco next ... Rutter, Chairman and CEO of Synergenics LLC ... fresh and relevant perspectives on,the regulatory implications of ...
... 18 JADO Technologies GmbH,the leading developer of ... Phase IIa clinical trial of its lead RAFT ... a topical,formulation of miltefosine, exerts its anti- inflammatory ... lipid membrane of cells that,play a role in ...
Cached Biology Technology:New filter clears up fiber optic communications 2New filter clears up fiber optic communications 3Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 3
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market ... Report: The Convergence of Commerce and Privacy" forecasts ... mobile biometric apps will be downloaded to smart ... The mobile biometrics market is projected to generate ... revenue during the seven-year forecast period.    ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... science takes a giant leap forward with a new ... new $1.5 million per year Pedo-Biometrics Research and Identity ... Ottawa, Canada, company currently relocating operations to the U.S., ... of identification uses, from security to detecting the onset ...
... Santa Barbara, Calif. As spatial planning is used increasingly ... to determine the best ways to use and refine the ... (MPAs), one of the most common methods, which limit or ... paper published in the early edition of the Proceedings ...
... Technology (Caltech) pioneered the study of the link ... disorders such as autism a decade ago. Since ... with autism, as well as epidemiological studies, have ... system and autism spectrum disorder. What has ...
Cached Biology News:Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 2Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 3Refining the tool kit for sustainable fisheries 2Refining the tool kit for sustainable fisheries 3Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3
...
...
... Transfer Vector is a derivative of the pAcHLT-A ... blue fluorescent protein (BFP), followed by a 6xHis ... are expressed as BFP-6xHis fusion proteins when cloned ... I, Stu I, Sac I, Not I, Pst ...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: